Study of actinium therapy for advanced soft tissue sarcoma
Part of Cancer clinical trials.
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have soft tissue sarcoma that has come back or not responded to treatment.
- You must have had at least one prior treatment for your sarcoma.
- Your tumor must be measurable (can be seen on scans) and show a specific marker on a PET scan.
- You must be in good general health (able to do daily activities) and have adequate organ function, including blood counts, liver, and kidney function.
- You must agree to use effective birth control if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This trial tests a combination of chemotherapy, radiation, and two newer drugs (anlotinib and bempegaldesleukin) for people with advanced soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of targeted therapy, chemotherapy, and radiation for advanced soft tissue sarcoma that has not responded to standard treatment. It aims to see if the combination can help patients live longer or shrink their tumors.
This trial tests whether combining seed radiation (iodine-125 placed in/near the tumor) with fluzoparib can better control advanced, hard-to-remove soft tissue sarcoma. It may help shrink tumors and slow progression, but you must meet several cancer, health, and safety requirements.
This trial tests a new combination of radiation therapy and an immunotherapy approach (called PraG) for people with advanced soft tissue sarcoma that can't be removed by surgery or has spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Advanced Soft-tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.